Skip to main
  1. Stocks
  2. Edwards Lifesciences
  3. Forecast
EW

Edwards Lifesciences (EW) Stock Forecast & Price Target

Edwards Lifesciences (EW) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 39%
Buy 44%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Edwards Lifesciences is positioned for a multiyear structural growth opportunity because PROGRESS, together with real-world evidence from Généreux and Kardigan, suggests moderate AS is both common and clinically meaningful rather than a narrow edge case. The registry found 78.7% of 35,343 moderate AS patients had at least one at-risk feature, while about 45,000-patient Kardigan data showed roughly 27% progressed rapidly, reinforcing that earlier intervention could expand TAVR demand beyond severe disease alone. That thesis is supported by execution: Q3 revenue rose 11.2% ex-FX to $1.72B, TAVR sales increased 8.8% to $1.24B, and FY26 guidance was raised to about 11.5% growth with adj. EPS of $2.97-$3.05.

Bears say

Edwards Lifesciences is facing a negative outlook because its growth depends on continued expansion in TAVR and TMTT, yet the company itself flags lower-than-anticipated TAVR penetration, weaker-than-expected adoption of the TMTT portfolio, and setbacks in TMVR development that could limit commercialization. It also faces competitive pressure globally from newer entrants and existing rivals, plus regulatory delays, clinical trial failures, and intellectual property challenges that could erode share and delay product launches. On top of that, macro and operating headwinds such as staffing shortages, supply chain or manufacturing disruptions, FX volatility, pricing pressure, and economic or political uncertainty in developed and emerging markets threaten margins and the roughly 60% of sales generated outside the US.

Edwards Lifesciences (EW) has been analyzed by 18 analysts, with a consensus rating of Buy. 39% of analysts recommend a Strong Buy, 44% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Edwards Lifesciences and is not a guaranteed prediction by Public.com or investment advice.

Edwards Lifesciences (EW) Analyst Forecast & Price Prediction

Get the latest Edwards Lifesciences (EW) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Edwards Lifesciences (EW)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Edwards Lifesciences (EW) Forecast

Analysts have given Edwards Lifesciences (EW) a Buy based on their latest research and market trends.

According to 18 analysts, Edwards Lifesciences (EW) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $110.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $110.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Edwards Lifesciences (EW)


Edwards Lifesciences (EW) Analyst Forecast & Price Prediction

Get the latest Edwards Lifesciences (EW) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Edwards Lifesciences (EW)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover EW stock data and trends